Huapont Life SciencesLtd (SZSE:002004) Is Posting Promising Earnings But The Good News Doesn't Stop There
Huapont Life SciencesLtd (SZSE:002004) Is Posting Promising Earnings But The Good News Doesn't Stop There
The market seemed underwhelmed by last week's earnings announcement from Huapont Life Sciences Co.,Ltd. (SZSE:002004) despite the healthy numbers. We did some analysis to find out why and believe that investors might be missing some encouraging factors contained in the earnings.
市场似乎对华邦健康科技股份有限公司(SZSE:002004)上周的盈利公告感到失望,尽管数字是健康的。我们进行了一些分析,以找出原因,并相信投资者可能忽略了盈利中包含的一些鼓舞人心的因素。
How Do Unusual Items Influence Profit?
非常规项目如何影响利润?
For anyone who wants to understand Huapont Life SciencesLtd's profit beyond the statutory numbers, it's important to note that during the last twelve months statutory profit was reduced by CN¥265m due to unusual items. It's never great to see unusual items costing the company profits, but on the upside, things might improve sooner rather than later. When we analysed the vast majority of listed companies worldwide, we found that significant unusual items are often not repeated. And, after all, that's exactly what the accounting terminology implies. If Huapont Life SciencesLtd doesn't see those unusual expenses repeat, then all else being equal we'd expect its profit to increase over the coming year.
对于任何想要了解华邦生命科学有限责任公司利润超出法定数字的人,重要的是要注意,在过去十二个月内,由于飞凡事项,法定利润减少了人民币26500万元。看到飞凡事项损害公司利润从未是好事,但从积极的一面来看,事情可能比你想的更快好转。当我们分析全球大多数上市公司时,我们发现重大飞凡事项通常不会重复。毕竟,这正是会计术语意味着的。如果华邦生命科学有限责任公司不再以此类飞凡开支重复出现,其他条件相等,我们预期其利润在未来一年内将增加。
Note: we always recommend investors check balance sheet strength. Click here to be taken to our balance sheet analysis of Huapont Life SciencesLtd.
注意:我们始终建议投资者检查资产负债表的实力。单击此处查看我们对华邦生命科学有限责任公司资产负债表分析。
Our Take On Huapont Life SciencesLtd's Profit Performance
我们对华邦生命科学有限责任公司的利润表现看法
Unusual items (expenses) detracted from Huapont Life SciencesLtd's earnings over the last year, but we might see an improvement next year. Based on this observation, we consider it likely that Huapont Life SciencesLtd's statutory profit actually understates its earnings potential! And the EPS is up 13% over the last twelve months. The goal of this article has been to assess how well we can rely on the statutory earnings to reflect the company's potential, but there is plenty more to consider. Keep in mind, when it comes to analysing a stock it's worth noting the risks involved. Every company has risks, and we've spotted 3 warning signs for Huapont Life SciencesLtd (of which 2 are a bit concerning!) you should know about.
去年,飞凡科技有限公司的非经常性项目(支出)抵消了收益,但我们可能在明年看到改善。基于这一观察结果,我们认为飞凡科技有限公司的法定利润实际上低估了其盈利潜力!上述十二个月中,每股收益提高了13%。本文的目标是评估我们能否依靠法定收益来反映公司的潜力,但还有很多要考虑的。请记住,当分析股票时,值得注意涉及的风险。每家公司都有风险,我们已经发现了华邦健康生命科学有限公司的3个警告信号(其中2个有点令人担忧!)您应该知道。
Today we've zoomed in on a single data point to better understand the nature of Huapont Life SciencesLtd's profit. But there are plenty of other ways to inform your opinion of a company. For example, many people consider a high return on equity as an indication of favorable business economics, while others like to 'follow the money' and search out stocks that insiders are buying. So you may wish to see this free collection of companies boasting high return on equity, or this list of stocks with high insider ownership.
今天我们聚焦于一个数据点,以更好地了解飞凡科技有限公司利润的性质。但有许多其他方法可以帮助您了解公司。例如,许多人认为高股本回报率是有利业务经济的指标,而其他人则喜欢‘追逐资金’并寻找内部人员正在购买的股票。因此,您可能希望查看这一免费组合的公司,这些公司标榜高股本回报率,或查看这份具有高内部所有权的股票清单。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
对本文有任何反馈?对内容有任何疑虑?请直接与我们联系。或者,发送电子邮件至editorial-team@simplywallst.com。
这篇文章是Simply Wall St的一般性文章。我们根据历史数据和分析师预测提供评论,只使用公正的方法论,我们的文章并不意味着提供任何金融建议。文章不构成买卖任何股票的建议,也不考虑您的目标或您的财务状况。我们的目标是带给您基本数据驱动的长期关注分析。请注意,我们的分析可能不考虑最新的价格敏感公司公告或定性材料。Simply Wall St没有任何股票头寸。